Universität Rostock, 2021
Abstract: This study investigates the safety of stem cell therapy combined with CABG to improve myocardial function after myocardial infarction. The patient groups of the PERFECT RCT Phase III were further analyzed in the scope of this work to placebo, stem cell, responder and non-responder groups. The outcome of this analysis showed an increase in the incidence rate of non-serious arrhythmias (SVES and VES) in stem cell group but also showed a significant reduction in this incidence rate over a period of time of up to 180 days only in the responder subgroup to the therapy.
doctoral thesis free access